News on research grants, RFPs, government funding trends in genetics, genomics, and molecular diagnostics.
Framingham, Massachusetts-based Kephera's tests is intended to be used to differentiate neurocysticercosis from other causes of seizures in patients.
BIOASTER and Mologic will develop and clinically evaluate a test prototype for detecting O. volvulus antibodies in blood with high specificity.
The funding supports development of a low-cost platform for detection of antimicrobial resistance elements in complex microbial communities.
Under a contract with BARDA, First Light is developing a digital imaging-based diagnostics platform, as well as tests for anthrax and urinary tract infections.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
